Novo Nordisk (NOVOB DC) to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Importance
Level 1
- Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved
- Wegovy® (semaglutide 2.4 mg and 7.2 mg) clinical and real-world data exploring its role in managing menopausal symptoms, including weight gain and migraine, and lowering cardiovascular risk
- Data on next-generation obesity pipeline, including the advanced combined amylin and GLP-1 receptor analogues